title: Drug-induced hypersensitivity syndrome followed by persistent arthritis.
authors.forename: Hironori
authors.initials: H
authors.lastname: Morito
authors.forename: Kohei
authors.initials: K
authors.lastname: Ogawa
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Kobayashi
authors.forename: Takaya
authors.initials: T
authors.lastname: Fukumoto
authors.forename: Hideo
authors.initials: H
authors.lastname: Asada
mesh_terms: D000889:Anti-Arrhythmia Agents / Q000009:adverse effects*; D018771:Arthralgia / Q000188:drug therapy / Q000821:virology; D001168:Arthritis / Q000139:chemically induced* / Q000188:drug therapy / Q000821:virology; D000068579:Celecoxib; D002908:Chronic Disease; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use; D004279:DNA, Viral / Q000097:blood; D004342:Drug Hypersensitivity / Q000175:diagnosis* / Q000188:drug therapy / Q000821:virology; D004359:Drug Therapy, Combination; D005076:Exanthema / Q000139:chemically induced / Q000175:diagnosis* / Q000188:drug therapy / Q000821:virology; D005260:Female; D015654:Herpesvirus 6, Human / Q000302:isolation & purification; D006801:Humans; D019278:Matrix Metalloproteinase 3 / Q000097:blood; D008801:Mexiletine / Q000009:adverse effects*; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D011720:Pyrazoles / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000889:Anti-Arrhythmia Agents; D052246:Cyclooxygenase 2 Inhibitors; D004279:DNA, Viral; D011720:Pyrazoles; D013449:Sulfonamides; D008801:Mexiletine; D011239:Prednisolone; C511768:MMP3 protein, human; D019278:Matrix Metalloproteinase 3; D000068579:Celecoxib